Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.

ABSTRACT:

Importance

Ocular surface events are a class effect of microtubule-inhibitor payload-containing antibody-drug conjugates (ADCs); the mechanism underlying these events has not been fully elucidated.

Objective

To characterize corneal epithelial changes in patients with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin, a maleimidocaproyl monomethyl auristatin-F (MMAF)-containing ADC.

Design, setting, and participants

This multicenter, phase 3b case series study was conducted in the US from March 26, 2020, to November 21, 2022, among adults with RRMM. Data were analyzed from May 2021 to May 2023.

Exposure

Prior or ongoing treatment with belantamab mafodotin.

Main outcomes and measures

The primary end point included pathologic

SUBMITTER: Lee V 

PROVIDER: S-EPMC12062993 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature